Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

AVROBIO Inc

Healthcare US AVRO

1.4USD
-0.02(1.41%)

Last update at 2024-06-20T20:04:00Z

Day Range

1.381.44
LowHigh

52 Week Range

0.881.65
LowHigh

Fundamentals

  • Previous Close 1.42
  • Market Cap66.44M
  • Volume204382
  • P/E Ratio2.18
  • Dividend Yield-%
  • EBITDA-66.01200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM0.68

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -105.89000M -119.12600M -119.71200M -72.96500M -46.36100M
Minority interest - - - - -
Net income -106.04700M -117.72700M -118.50500M -72.11500M -46.36100M
Selling general administrative 33.25M 35.73M 32.99M 20.84M 11.15M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 1.44M 1.40M 1.21M 0.85M 0.38M
Ebit -106.87400M -120.24000M -121.43500M -76.65900M -46.62300M
Ebitda -105.43400M -118.84100M -120.22800M -75.80900M -46.24300M
Depreciation and amortization 1.44M 1.40M 1.21M 0.85M 0.38M
Non operating income net other -0.45600M - 0.52M 2.84M -0.11800M
Operating income -105.43400M -118.84100M -120.22800M -75.80900M -46.24300M
Other operating expenses 105.43M 118.84M 120.23M 75.81M 46.24M
Interest expense 0.30M -0.22400M 0.72M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - 0.72M 2.93M 1.73M
Net interest income -0.29900M -0.22400M 0.72M 2.93M 1.73M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.16M -1.39900M -1.20700M -0.85000M -0.11800M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 105.43M 118.84M 120.23M 75.81M 46.24M
Cost of revenue - - - - 0.00000M
Total other income expense net -0.45600M -0.28500M 0.52M 2.84M -0.11800M
Discontinued operations - - - - -
Net income from continuing ops -105.89000M -119.12600M -119.71200M -72.96500M -46.36100M
Net income applicable to common shares -105.89000M -119.12600M -119.71200M -72.96500M -48.60400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 101.09M 103.95M 203.84M 271.23M 200.51M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.96M 7.11M 9.58M 7.56M 8.66M
Total liab 6.35M 28.58M 34.36M 16.89M 14.50M
Total stockholder equity 94.74M 75.37M 169.48M 254.34M 186.01M
Deferred long term liab - - - 0.28M 0.13M
Other current liab 5.45M 10.73M 15.90M 13.93M 10.07M
Common stock 0.00400M 0.00400M 0.00400M 0.00400M 0.00300M
Capital stock 0.00400M 0.00400M 0.00400M 0.00400M 0.00300M
Retained earnings -477.27500M -489.43200M -383.54200M -264.41600M -144.70400M
Other liab - - 0.03M 0.28M 0.48M
Good will - - - - -
Other assets 0.00000M - 0.57M 0.93M 1.12M
Cash 98.30M 92.56M 189.57M 259.68M 187.04M
Cash and equivalents - - - - -
Total current liabilities 6.35M 12.12M 19.39M 16.61M 14.02M
Current deferred revenue - - - - -
Net debt -97.42500M -75.10100M -174.62200M -259.68200M -187.04300M
Short term debt 0.88M 1.00M - - -
Short long term debt - - - - -
Short long term debt total 0.88M 17.46M 14.95M - -
Other stockholder equity 572.01M 564.80M 553.01M 518.76M 330.71M
Property plant equipment - 2.89M 4.13M 3.06M 3.70M
Total current assets 100.26M 99.67M 199.15M 267.24M 195.70M
Long term investments - - - - -
Net tangible assets - 75.37M 169.48M 254.34M 186.01M
Short term investments - - - - -
Net receivables - 0.27M 2.70M 2.56M 2.14M
Long term debt - 15.28M 14.95M - -
Inventory - -0.26900M -2.69700M -2.56200M -2.14000M
Accounts payable 0.03M 0.38M 3.49M 2.68M 3.95M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -1.23400M
Additional paid in capital - - - - -
Common stock total equity - 0.00400M - 0.00400M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - -489.43200M - -264.41600M -144.70400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.40M 0.32M 0.57M 0.93M 1.12M
Deferred long term asset charges - - - - -
Non current assets total 0.83M 4.27M 4.69M 3.99M 4.81M
Capital lease obligations 0.88M 1.19M - - -
Long term debt total - 15.28M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.26700M -2.46100M -1.17700M -1.58500M -1.83200M
Change to liabilities -7.00800M 0.80M -0.88100M 2.95M 7.33M
Total cashflows from investing activities -0.26700M -2.46100M -1.17700M -1.58500M -1.83200M
Net borrowings - 15.00M 15.00M 15.00M 15.00M
Total cash from financing activities 0.26M 30.37M 172.62M 129.99M 160.29M
Change to operating activities - 0.49M 5.12M -3.20900M 2.16M
Net income -105.89000M -119.12600M -119.71200M -72.96500M -46.36100M
Change in cash -97.21300M -70.11500M 72.64M 60.74M 120.81M
Begin period cash flow 190.06M 260.17M 187.53M 126.79M 5.99M
End period cash flow 92.85M 190.06M 260.17M 187.53M 126.79M
Total cash from operating activities -97.20800M -98.02500M -98.80300M -67.66800M -37.64800M
Issuance of capital stock 0.00000M 14.55M 172.18M 129.47M 162.27M
Depreciation 1.44M 1.40M 1.21M 0.85M 0.38M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.20M -0.20500M 0.17M 129.99M 104.03M
Other cashflows from financing activities 0.06M 16.03M 0.27M 0.53M 56.27M
Change to netincome 11.91M 18.41M 15.46M 6.63M 4.12M
Capital expenditures 0.27M 2.46M 1.18M 1.58M 1.83M
Change receivables - - - - -
Cash flows other operating 2.34M - 1.20M -5.12900M -3.15200M
Exchange rate changes - - - - -
Cash and cash equivalents changes -97.21300M - 72.64M 60.74M 120.81M
Change in working capital -7.40100M 1.30M 4.24M -2.18100M 4.18M
Stock based compensation 11.52M 18.58M 15.63M 6.80M 2.20M
Other non cash items 3.12M -0.17400M -0.16300M -0.17200M -0.06800M
Free cash flow -97.47500M -100.48600M -99.98000M -69.25300M -39.48000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
AVRO
AVROBIO Inc		 -0.02 1.41% 1.40 2.18 - - 0.60 0.57
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AVROBIO Inc

100 Technology Square, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Mr. Geoff MacKay BSc Co- Founder, Pres, CEO & Director 1966
Mr. Erik John Ostrowski M.B.A. CFO & Treasurer 1973
Mr. Jeffrey Medin Ph.D. Scientific Founder NA
Mr. Matthew Arnold Head of Operations NA
Mr. Steven N. Avruch J.D. Chief Legal Officer & Sec. 1961
Ms. Monique Da Silva Sr. VP of Corp. Communications NA
Ms. Deanna M. Petersen MBA Chief Bus. Officer 1962
Ms. Azadeh Golipour Ph.D. Chief Technology Officer NA
Mr. Andreas Kouri Sr. VP of Global Supply Chain & External Manufacturing NA
Dr. Essra Ridha FFPM, M.D. Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.